SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic ⁶⁴Cu SAR-bisPSMA trial (COBRA NCT05249127^[1]) for patients with prostate...